The Degron team has designed and synthesized a unique molecular glue degrader (MGD) compound library based on our decades of research experience in protein ubiquitin and degradation. Degron discovers novel disease targets that can be degraded by its library MGDs, including those considered “undruggable” by traditional small molecule inhibitors or monoclonal antibodies, via phenotypic, proteomic, and induced-proximity screens. Degron MGD-target biology is supported by established tools covering cell-based assays, biochemical and biophysical assays, and mouse genetics. Degron also predicts potential MGD targets by analyzing its in-house chemical and target database and uncovers specific degraders of selected targets by screening its proprietary MGD library. Our fully validated compounds are moving into preclinical and clinical development to treat cancer, inflammation, metabolic disorders, and other diseases.